The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
Open accessAbstract
Background Following the emergency use authorisation of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 (international non-proprietary name tozinameran) in Israel, the Ministry of Health (MoH) launched a campaign to immunise the 6·5 million residents of Israel aged 16 years and older. We estimated the real-world effectiveness of two doses of BNT162b2 against a range of SARS-CoV-2 outcomes and to evaluate the nationwide public-health impact following the widespread introduction of the vaccine.Methods We used national surveillance data from the first 4 months of the nationwide vaccination campaign to ascertain incident cases of laboratory-confirmed SARS-CoV-2 infections and outcomes, as well as vaccine uptake in residents of Israel aged 16 years and older. Vaccine effectiveness against SARS-CoV-2 outcomes (asymptomatic infection, symptomatic infection, and COVID-19-related hospitalisation, severe or critical hospitalisation, and death) was calculated on the basis of incidence rates in fully vaccinated individuals (defined as those for whom 7 days had passed since receiving the second dose of vaccine) compared with rates in unvaccinated individuals (who had not received any doses of the vaccine), with use of a negative binomial regression model adjusted for age group (16-24, 25-34, 35-44, 45-54, 55-64, 65-74, 75-84, and ≥85 years), sex, and calendar week. The proportion of spike gene target failures on PCR test among a nationwide convenience-sample of SARS-CoV-2-positive specimens was used to estimate the prevelance of the B.1.1.7 variant.Findings During the analysis period (Jan 24 to April 3, 2021), there were 232 268 SARS-CoV-2 infections, 7694 COVID-19 hospitalisations, 4481 severe or critical COVID-19 hospitalisations, and 1113 COVID-19 deaths in people aged 16 years or older. By April 3, 2021, 4 714 932 (72·1%) of 6 538 911 people aged 16 years and older were fully vaccinated with two doses of BNT162b2. Adjusted estimates of vaccine effectiveness at 7 days or longer after the second dose were 95·3% (95% CI 94·9-95·7; incidence rate 91·5 per 100 000 person-days in unvaccinated vs 3·1 per 100 000 person-days in fully vaccinated individuals) against SARS-CoV-2 infection, 91·5% (90·7-92·2; 40·9 vs 1·8 per 100 000 person-days) against asymptomatic SARS-CoV-2 infection, 97·0% (96·7-97·2; 32·5 vs 0·8 per 100 000 person-days) against symptomatic COVID-19, 97·2% (96·8-97·5; 4·6 vs 0·3 per 100 000 person-days) against COVID-19-related hospitalisation, 97·5% (97·1-97·8; 2·7 vs 0·2 per 100 000 person-days) against severe or critical COVID-19-related hospitalisation, and 96·7% (96·0-97·3; 0·6 vs 0·1 per 100 000 person-days) against COVID-19-related death. In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined. 8006 of 8472 samples tested showed a spike gene target failure, giving an estimated prevalence of the B.1.1.7 variant of 94·5% among SARS-CoV-2 infections.Interpretation Two doses of BNT162b2 are highly effective across all age groups (≥16 years, including older adults aged ≥85 years) in preventing symptomatic and asymptomatic SARS-CoV-2 infections and COVID-19-related hospitalisations, severe disease, and death, including those caused by the B.1.1.7 SARS-CoV-2 variant. There were marked and sustained declines in SARS-CoV-2 incidence corresponding to increasing vaccine coverage. These findings suggest that COVID-19 vaccination can help to control the pandemic.Funding None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For context, for a state that is near the herd immunity threshold (70-80% based on recent estimates 22 ), a discrepancy of 10 percentage points in vaccination rates could be the difference between containment and uncontrolled exponential growth in new SARS-CoV-2 infections.”
From Unrepresentative big surveys significantly overestimated US vaccine uptake (2021) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Real-world setting studies performed, few months into vaccination campaigns, showed high effectiveness of these vaccines [1-8].”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“As previously reported for other vaccines29–33, the neutralizing antibody titres against certain SARS-CoV-2 variants, such as the B.1.351 (Beta) and B.1.617.2 (Delta) variants, were lower than those against the parental strain WA1/2020.”
From Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine (2022) · cites this paper as [30]
Experimental — accuracy not yet measuredIn the citing paper
“Observational postmarketing studies, including this analysis, have consistently demonstrated a strong association between vaccination and risk reductions in COVID-19 hospitalization in immunocompetent individuals, suggesting that the high efficacy observed in mRNA clinical trials translates into beneficial effects in the community setting.2,3,10”
From Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity (2021) · cites this paper as [3]
In the citing paper
“A randomized, controlled trial and real-world studies have shown vaccine efficacy of 94 to 95% with the BNT162b2 vaccine (Pfizer–BioNTech) and vaccine effectiveness in preventing symptomatic coronavirus disease 2019 (Covid-19) 7 days or more after receipt of the second dose of vaccine.1,3-5”
From Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months (2021) · cites this paper as [4]
In the citing paper
“At the time of this study, the B.1.1.7 variant was the most widespread variant in Israel and accounted for up to 94.5% of SARS-CoV-2 isolates.1,16”
From Covid-19 Breakthrough Infections in Vaccinated Health Care Workers (2021) · cites this paper as [1]
In the citing paper
“Since its rollout in late 2020 in Israel, the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) has been highly effective in preventing clinically significant coronavirus disease 2019 (Covid-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1-3”
From Covid-19 Breakthrough Infections in Vaccinated Health Care Workers (2021) · cites this paper as [1]
In the citing paper
“We identified the B.1.1.7 variant in 85% of cases, similar to its prevalence in the community.1,16”
From Covid-19 Breakthrough Infections in Vaccinated Health Care Workers (2021) · cites this paper as [1]
In the citing paper
“In cohort studies from Israel and Qatar, the BNT162b vaccine also retained greater than 90% efficacy against this variant 210,211 (TABLe 2).”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [210]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Elm, E. V., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · BMJ · doi:10.1136/bmj.39335.541782.ad · Cited by 10,766
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
"Herd Immunity": A Rough Guide
Fine, P. E., Eames, K. T. D., & Heymann, D. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir007 · Cited by 1,256
Hall, V. J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., Wellington, E., Stowe, J., Gillson, N., Atti, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00790-x · Cited by 767
Vasileiou, E., Simpson, C. R., Shi, T., Kerr, S., Agrawal, U., Akbari, A., Bedston, S., Beggs, J., Bradley, D., Chuter, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00677-2 · Cited by 549
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
Muik, A., Wallisch, A.-K., Sänger, B., Swanson, K. A., Mühl, J., Chen, W., Cai, H., Maurus, D., Sarkar, R., Türeci, Ö., et al. (2021) · Science · doi:10.1126/science.abg6105 · Cited by 515
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
Amit, S., Regev-Yochay, G., Afek, A., Kreiss, Y., & Leshem, E. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00448-7 · Cited by 306
SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants
Moore, J. P., & Offit, P. A. (2021) · JAMA · doi:10.1001/jama.2021.1114 · Cited by 220
Cited by
Sorted by citations
Items 401–500 of 1,001
Cui, X., Wang, P., & Wei, Z. (2021) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2021.01064 · Cited by 25
Walsh, K. A., Tyner, B., Broderick, N., Harrington, P., O’Neill, M., Fawsitt, C. G., Cardwell, K., Smith, S. M., Connolly, M. A., & Ryan, M. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2285 · Cited by 24
Waitzberg, R., Triki, N., Alroy‐Preis, S., Lotan, T., Shiran, L., & Ash, N. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182111212 · Cited by 25
Self-citationGualano, B., Lemes, Í. R., da Silva, R. P., Pinto, A. J., Mazzolani, B. C., Smaira, F. I., Sieczkowska, S. M., Aikawa, N. E., Pasoto, S. G., Ribeiro, A. C. D. M., et al. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.12.016 · Cited by 34
Smith, A. P., Williams, E. P., Plunkett, T. R., Selvaraj, M., Lane, L. C., Zalduondo, L., Xue, Y., Vogel, P., Channappanavar, R., Jonsson, C. B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.894534 · Cited by 28
Paternina-Caicedo, Á. J., Jit, M., Alvis‐Guzmán, N., Fernández, J. C., Hernández, J., Paz-Wilches, J., Rojas-Suárez, J. A., Castell, C. R. D., Alvis-Zakzuk, N. J., Smith, A. D., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100296 · Cited by 25
Vaccines against SARS-CoV-2 variants and future pandemics
Park, T., Hwang, H., Moon, S., Kang, S. G., Song, S., Kim, Y. H., Kim, H., Ko, E., Yoon, S., Kang, S., et al. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2110075 · Cited by 23
Dellino, M., Cascardi, E., Vinciguerra, M., Lamanna, B., Malvası, A., Scacco, S., Acquaviva, S., Pinto, V., Vagno, G. D., Cormio, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169136 · Cited by 25
Nasreen, S., Febriani, Y., García, H. A. V., Zhang, G., Tadrous, M., Buchan, S. A., Righolt, C. H., Mahmud, S. M., Janjua, N. Z., Krajden, M., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac634 · Cited by 23
Bello‐Chavolla, O. Y., Antonio‐Villa, N. E., Valdés‐Ferrer, S. I., Fermín‐Martínez, C. A., Fernández‐Chirino, L., Vargas‐Vázquez, A., Ramírez‐García, D., Mancilla-Galindo, J., Kammar‐García, A., Ávila‐Funes, J. A., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.01.040 · Cited by 32
“[16] Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al.”
Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics
Pavan, M., & Moro, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054401 · Cited by 25
“Despite worries about the higher transmissibility compared to other circulating variants at the time [106,107], clinical studies demonstrated how mAbs, CP, and especially vaccines, were still able to confer protection against B.1.1.7 [108–110], containing its impact on the sanitary system [111].”
BackgroundInfluentialXue, S., & Abhayaratne, C. (2023) · IEEE Access · doi:10.1109/access.2023.3260632 · Cited by 24
“Despite the vaccination efforts in full force and many countries have cancelled public COVID rules, vanquishing COVID-19 and achieving herd immunity are still theoretically unreachable in the foreseeable future [4], [5] due to its possible reinfection rate [6], [7].”
BackgroundGao, Y., Liu, M., Li, Z., Xu, J., Zhang, J., & Tian, J. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.04.014 · Cited by 25
“We excluded RCTs investigating only patients with severe and critical COVID-19 or people with suspected or probable COVID19.”
InfluentialTan, W. C., Tan, J. Y. J., Lim, J. S. J., Tan, R. S. Y. C., Lee, A. R. Y. B., Leong, F. L., Lee, S. C., Chai, L. Y. A., Tan, T. T., Malek, M. I. B. A., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2271 · Cited by 23
SARS-CoV-2 and COVID-19: A Narrative Review
Blann, A. D., & Heitmar, R. (2022) · British Journal of Biomedical Science · doi:10.3389/bjbs.2022.10426 · Cited by 25
Disentangling post-vaccination symptoms from early COVID-19
Canas, L. S., Österdahl, M. F., Deng, J., Hu, C. Y., Selvachandran, S., Polidori, L., May, A., Molteni, E., Murray, B. A. K., Chen, L., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101212 · Cited by 21
Efectividad y seguridad de las vacunas para el SARS-CoV-2 actualmente disponibles
Marco, J. J. G., Pasquín, M. J. Á., & Martín, S. M. (2021) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2021.07.001 · Cited by 25
Ben‐Dov, I. Z., Oster, Y., Tzukert, K., Alster, T., Bader, R., Israeli, R., Asayag, H., Aharon, M., Burstein, I., Pri-Chen, H., et al. (2022) · Journal of Nephrology · doi:10.1007/s40620-021-01210-y · Cited by 24
“Iddo Z. Ben‑Dov1 · Yonatan Oster2 · Keren Tzukert1 · Talia Alster1 · Raneem Bader3 · Ruth Israeli1 · Haya Asayag1 · Michal Aharon1 · Ido Burstein1 · Hadas Pri‑Chen1 · Ashraf Imam3 · Roy Abel1 · Irit Mor‑Yosef Levi1 · Abed Khalaileh3 · Esther Oiknine‑Djian2 · Aharon Bloch1 · Dana G. Wolf2 · Michal Dranitzki Elhalel1 *…”
BackgroundInfluentialKo, Y. K., Furuse, Y., Ninomiya, K., Otani, K., Akaba, H., Miyahara, R., Imamura, T., Imamura, T., Cook, A. R., Saito, M., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.01.036 · Cited by 23
Chin, E. T., Leidner, D., Zhang, Y., Long, E., Prince, L., Schrag, S. J., Verani, J. R., Wiegand, R. E., Alarid‐Escudero, F., Goldhaber‐Fiebert, J. D., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1032 · Cited by 24
“Augmenting efficacy evidence from clinical trials [1, 2], observational studies among healthcare workers [3, 4], adults aged ≥65 years [5], and the general community [6, 7] have reported levels of protection from full vaccination ranging from 89% to 95%.”
Ung, C. O. L., Yuanjia, H., Hu, H., & Bian, Y. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07191-y · Cited by 24
“Moreover, marked and sustained declines in the incidence of COVID-19 infections corresponding to increasing vaccine coverage had been reported, suggesting that Covid-19 vaccination could help to control the pandemic [13].”
BackgroundBeeraka, N. M., Sukocheva, O. A., Lukina, E., Liu, J., & Fan, R. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2346 · Cited by 23
“in one of the clinical trials and the vaccine showed 95% efficacy (30 μg per dose, two doses) and exhibited an efficient level of protection against the symptomatic COVID‐19.(170) BNT162b2 can also neutralise SARS‐CoV‐2 variants and deliver combined adaptive”
BackgroundInfluentialMitoxantrone modulates a heparan sulfate-spike complex to inhibit SARS-CoV-2 infection
Zhang, Q., Radvák, P., Lee, J., Xu, Y., Cao-Dao, V., Xu, M., Zheng, W., Chen, C. Z., Xie, H., & Ye, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-10293-x · Cited by 25
Impact of prior vaccination on clinical outcomes of patients with COVID-19
Seo, W. J., Kang, J., Kang, H. K., Park, S. H., Koo, H., Park, H. K., Lee, S.-S., Song, J. E., Kwak, Y. G., & Kang, J. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2069516 · Cited by 22
“that currently available vaccines are effective in preventing SARS-CoV-2 infection [22-24].”
BackgroundJohnson, K. W., Patel, S. A., Thapi, S., Jaladanki, S. K., RAO, A., Nirenberg, S., & Lala, A. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.05.008 · Cited by 23
“1 increased risk of severe complications, including death, of patients with heart failure (HF) who have been hospitalized due to COVID-19.(1-4) Vaccination against COVID-19 has been proven to be highly effective in preventing adverse outcomes in the general population, but concern about potential cardiovascular sequel…”
Individual-level social capital and COVID-19 vaccine hesitancy in Japan: a cross-sectional study
Machida, M., Kikuchi, H., Kojima, T., Nakamura, I., Saito, R., Nakaya, T., Hanibuchi, T., Takamiya, T., Odagiri, Y., Fukushima, N., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2086773 · Cited by 23
Κοντοπούλου, Κ., Nakas, C. T., & Papazisis, G. (2022) · Vaccines · doi:10.3390/vaccines10060876 · Cited by 24
“Real-world evidence from vaccine-rollout programs has shown that COVID-19 vaccines are highly effective against severe disease, hospitalization, and death, and they reduce asymptomatic infection and transmission among family members [1,2].”
BackgroundPlechatá, A., Vandeweerdt, C., Atchapero, M., Luong, T., Holz, C., Betsch, C., Dietermann, B., Schultka, Y., BOHM, R. M., & Makransky, G. (2022) · Computers in Human Behavior · doi:10.1016/j.chb.2022.107533 · Cited by 28
“The COVID-19 global pandemic declared in March 2020 is still a threat to public health, and increasing vaccine uptake is crucial to decrease hospitalization and death (Bozio et al., 2021; Haas et al., 2021).”
Martínez‐Baz, I., Miqueleiz, A., Egüés, N., Casado, I., Burgui, C., Echeverría, A., Navascués, A., Fernández-Huerta, M., Cenoz, M. G., Trobajo‐Sanmartín, C., et al. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.01.017 · Cited by 26
Paireau, J., Charpignon, M., Larrieu, S., Calba, C., Hozé, N., Boëlle, P., Thiébaut, R., Prague, M., & Cauchemez, S. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08106-1 · Cited by 23
“By the end of 2020 onwards, mass vaccination campaigns have helped mitigate the transmission of SARS-CoV-2 [2], while the concurrent emergence of more transmissible and immune escape variants of concern (VOC) has fostered virus spread [3].”
BackgroundFukuda, H., Maeda, M., & Murata, F. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.059 · Cited by 23
Marchand, G. J., Masoud, A. T., & Medi, S. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2230828 · Cited by 23
RetractedReynolds, L., Dewey, C. E., Asfour, G., & Little, M. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1229716 · Cited by 24
Aarstad, J., & Kvitastein, O. A. (2023) · Asian Pacific Journal of Health Sciences · doi:10.21276/apjhs.2023.10.1.6 · Cited by 25
Baum, U., Poukka, E., PALMU, A. A. I., Salo, H., Lehtonen, T., & Leino, T. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258704 · Cited by 21
“In another study from Israel, VE against asymptomatic and 205 symptomatic infection was 52% and 63%, respectively, in the third week after the first dose [11].”
BackgroundResultInfluentialImmunogenicity of a BNT162b2 vaccine booster in health-care workers
Saiag, E., Goldshmidt, H., Sprecher, E., Ben-Ami, R., & Bomze, D. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00272-x · Cited by 22
COVID-19 vaccine boosters: What do we know so far?
Kherabi, Y., Fiolet, T., Rozencwajg, S., Salaün, J., & Peiffer‐Smadja, N. (2021) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2021.100959 · Cited by 22
Head, J. R., Andrejko, K. L., & Remais, J. V. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100133 · Cited by 22
COVID-19 Vaccine: Between Myth and Truth
Piccaluga, P. P., Guardo, A. D., Lagni, A., Lotti, V., Diani, E., Navari, M., & Gibellini, D. (2022) · Vaccines · doi:10.3390/vaccines10030349 · Cited by 22
“In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined [52].”
BackgroundCMR Imaging 6 Months After Myocarditis Associated with the BNT162b2 mRNA COVID-19 Vaccine
Amir, G., Rotstein, A., Razon, Y., Beer, G., Barak‐Corren, Y., Godfrey, M. E., Lakovsky, Y., Yaeger-Yarom, G., Yarden‐Bilavsky, H., & Birk, E. (2022) · Pediatric Cardiology · doi:10.1007/s00246-022-02878-0 · Cited by 22
“Since its introduction, the The Pfzer–BioNTech mRNA BNT162b2 COVID-19 vaccine has been shown to significantly decrease rates of infection, severe disease, and death due to COVID-19 infection, while side effects of the vaccine have been mild and mostly selflimiting [2, 3].”
BackgroundMueangpoon, K., Inchan, C., Kaewmuneechoke, P., Rattana, P., Budsratid, S., Japakiya, S., Ngamchaliew, P., & Vichitkunakorn, P. (2022) · Vaccines · doi:10.3390/vaccines10040627 · Cited by 22
“Previous evidence has shown that fully vaccinated people have a lower incidence rate of COVID-19 infection, COVID-19-related hospitalization, severe symptoms, and a lower mortality rate than unvaccinated people [2,3].”
BackgroundAddressing COVID-19 vaccine hesitancy
Kassianos, G. C., Puig‐Barberà, J., Dinse, H., Teufel, M., Türeci, Ö., & Pather, S. (2022) · Drugs in Context · doi:10.7573/dic.2021-12-3 · Cited by 22
COVID-19 vaccine-associated myocarditis
Morgan, M. C., Atri, L., Harrell, S., AlJaroudi, W., & Berman, A. E. (2022) · World Journal of Cardiology · doi:10.4330/wjc.v14.i7.382 · Cited by 23
Longet, S., Hargreaves, A., Healy, S., Brown, R. L., Hornsby, H. R., Meardon, N., Tipton, T., Barnes, E. J., Dunachie, S. J., Duncan, C. J. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953949 · Cited by 20
Intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2 induces neutralizing salivary IgA
Stolovich-Rain, M., Kumari, S., Friedman, A., Kirillov, S., Socol, Y., Billan, M., Pal, R. R., Das, K., Golding, P., Oiknine‐Djian, E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.933347 · Cited by 23
Lund, L. C., Støvring, H., Pottegård, A., Andersen, M. T., & Hallas, J. (2023) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2023.02.012 · Cited by 22
Cavillot, L., van Loenhout, J. A. F., Devleesschauwer, B., Wyndham-Thomas, C., Oyen, H. J. V., Ghattas, J., Blot, K. Y., den Borre, L. V., Billuart, M., Speybroeck, N., et al. (2023) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2023-220751 · Cited by 21
Aljabr, W. A., Alruwaili, M., Penrice-Randal, R., Alrezaihi, A. F., Harrison, A., Ryan, Y., Bentley, E. G., Jones, B., Alhatlani, B. Y., AlShahrani, D. A., et al. (2021) · mSphere · doi:10.1128/msphere.00219-21 · Cited by 23
Fiolet, T., Kherabi, Y., MacDonald, C. J., Ghosn, J., & Peiffer‐Smadja, N. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/z4x7t · Cited by 22
What Lessons can Be Learned From the Management of the COVID-19 Pandemic?
Quinn, G. A., Connolly, R., ÓhAiseadha, C. O., Hynds, P. D., Bagus, P., Brown, R. B., Cáceres, C. F., Craig, C. E. H., Connolly, M., Domingo, J. L., et al. (2025) · International Journal of Public Health · doi:10.3389/ijph.2025.1607727 · Cited by 24
Sotis, C., Romano, A., Reyes, R., & Allena, M. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18168800 · Cited by 21
“However, as existing vaccines have been proven to be safe and effective [8,9], these key industries are looking forward to better times, especially in light of the possible introduction of COVID-19 vaccine passports (hereafter, COVID passes).”
BackgroundKroidl, I., Mecklenburg, I., Schneiderat, P., Müller, K., Girl, P., Wölfel, R., Sing, A., Dangel, A., Wieser, A., & Höelscher, M. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.30.2100673 · Cited by 21
Kato, H., Miyakawa, K., Ohtake, N., Go, H., Yamaoka, Y., Yajima, S., Shimada, T., Goto, A., Nakajima, H., & Ryo, A. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.11.021 · Cited by 22
“274 and reducing disease severity range from 94% to 95% [4,5].”
Impacts of rapid mass vaccination against SARS-CoV2 in an early variant of concern hotspot
Paetzold, J., Kimpel, J., Bates, K., Hummer, M., Krammer, F., von Laer, D., & Winner, H. (2022) · Nature Communications · doi:10.1038/s41467-022-28233-8 · Cited by 21
Somekh, I., KhudaBukhsh, W. R., Root, E. D., Keinan‐Boker, L., Rempała, G. A., Simões, E. A. F., & Somekh, E. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac087 · Cited by 19
“This campaign was based on the BNT162b2 mRNA COVID-19 vaccine (PfizerBioNTech, Mainz, Germany) and was planned to include a large proportion of the Israeli adult population in a short time interval [1].”
MethodMALDI-TOF mass spectrometry of saliva samples as a prognostic tool for COVID-19
Lázari, L. C., Zerbinati, R. M., Rosa-Fernandes, L., Santiago, V. F., Rosa, K. F., Angeli, C. B., Schwab, G., Palmieri, M., Sarmento, D. J. D. S., Marinho, C. R. F., et al. (2022) · Journal of Oral Microbiology · doi:10.1080/20002297.2022.2043651 · Cited by 21
Aljamaan, F., Temsah, M., Alhasan, K., Alenezi, S., Alhaboob, A., Alrabiaah, A., Batais, M., Alshahrani, F., Assiri, R., Bafaqih, H., et al. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.06.007 · Cited by 18
Hagrass, A. I., Almadhoon, H. W., Al‐kafarna, M., Almaghary, B. K., Nourelden, A. Z., Fathallah, A. H., Hasan, M. T., Mohammed, Y. A., Al-Nabahin, A. O., Wafi, D. S., et al. (2022) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-022-04884-9 · Cited by 23
Immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in aged people
Vitallé, J., Pérez‐Gómez, A., Ostos, F. J., Gasca‐Capote, C., Jiménez‐León, M. R., Bachiller, S., Rivas‐Jeremías, I., Silva-Sánchez, M. D. M., Ruiz-Mateos, A. M., Martín-Sánchez, M. Á., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.161045 · Cited by 20
Khawaja, F., Papanicolaou, G. A., Dadwal, S., Pergam, S. A., Wingard, J. R., Boghdadly, Z. E., Abidi, M. Z., Waghmare, A., Shahid, Z., Michaels, L., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.10.010 · Cited by 21
Takayama, S., Namiki, T., Arita, R., Ono, R., Kikuchi, A., Ohsawa, M., Saito, N., Suzuki, S., Nakae, H., Kobayashi, S., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1008946 · Cited by 22
“Since the trial unexpectedly included only few elderly patients (aged >65 years), the threshold for age classification was defined as 45 years with reference to higher hospitalization rate in the age class of ≥45 years (Harrs et al., 2021).”
BackgroundRisk factors for severe Covid-19 breakthrough infections: an observational longitudinal study
Fredj, S. B., Ghammem, R., Zammit, N., Maatouk, A., Haddad, N., Haddad, N., Kachroudi, M., Senda, R., Ladhari, H., Ghodhbani, M. M., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07859-5 · Cited by 27
“Hence, the generalizability of our findings needs to be validated in other populations including younger ages and other national data resources, and extended to the fifth wave exploring the Omicron VOC with assessing the potential waning after full vaccination.”
BackgroundResultInfluentialCOVID-19 vaccine coverage targets to inform reopening plans in a low incidence setting
Conway, E. J., Walker, C. R., Baker, C. M., Lydeamore, M., RYAN, G. E., Campbell, T., Miller, J. C., Rebuli, N., Yeung, M., Kabashima, G., et al. (2023) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2023.1437 · Cited by 18
Assessing the risk of vaccine-driven virulence evolution in SARS-CoV-2
Miller, I. F., & Metcalf, C. J. E. (2022) · Royal Society Open Science · doi:10.1098/rsos.211021 · Cited by 22
Baltas, I., Boshier, F. A. T., Williams, C. A., Bayzid, N., Cotic, M., Guerra‐Assunção, J. A., Irish, D. N., Haque, T., Hart, J., Roy, S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab714 · Cited by 22
Education Attainment, Intelligence and COVID-19: A Mendelian Randomization Study
Li, G. H., Lam, S. K. K., Wong, I. C. K., Chu, J. K.-P., & Cheung, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10214870 · Cited by 21
“Notably, vaccination did not only protect individuals against the infection of SARS-CoV-2, but vaccines such as Pfizer-BioNTech BNT162b2 or ChAdOx1-S could also reduce the risk of COVID-19 related hospitalization [43,44], severe or critical COVID-19 related hospitalization [44], and mortality [43,44].”
BackgroundInsights into COVID-19 Delta variant (B.1.617.2)
Thye, A. Y.-K., Loo, K.-Y., Tan, K. B. C., Lau, J. M.-S., & Letchumanan, V. (2021) · Progress In Microbes & Molecular Biology · doi:10.36877/pmmb.a0000243 · Cited by 20
Terpos, E., Karalis, V., Ntanasis‐Stathopoulos, I., Apostolakou, F., Gumeni, S., Gavriatopoulou, M., Papadopoulos, D., Malandrakis, P., Papanagnou, E.-D., Korompoki, E., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000677 · Cited by 20
Dillon, G. A., Wolf, S. T., & Alexander, L. M. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00602.2021 · Cited by 20
Predictors of Real-World Parents’ Acceptance to Vaccinate Their Children Against the COVID-19
Galanis, P., Vraka, I. S., Siskou, O. C., Konstantakopoulou, O., Katsiroumpa, A., Moisoglou, I., & Καϊτελίδου, Δ. (2022) · Acta medica Lituanica · doi:10.15388/amed.2021.29.1.4 · Cited by 22
Zhou, F., Hu, T., Zhang, X., Lai, K., Chen, J., & Zhou, X. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.03.011 · Cited by 19
“Our research confirms that the role of vaccine policies in epidemic prevention and control, which were similar to previous studies conducted in Israel [37] and England [38], and based on modeling [16,17,19].”
Chandan, J. S., Brown, K. R., Simms-Williams, N., Camaradou, J., Bashir, N. Z., Heining, D., Aiyegbusi, O. L., Turner, G., Rivera, S. C., Hotham, R., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057885 · Cited by 20
Fan, Q., Shi, J., Yang, Y., Tang, G., Jiang, M., Li, J. J., Tang, J., Li, L., Wen, X., Zhang, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31693-7 · Cited by 19
Human mobility and infection from Covid-19 in the Osaka metropolitan area
Kato, H., & Takizawa, A. (2022) · npj Urban Sustainability · doi:10.1038/s42949-022-00066-w · Cited by 20
Al‐Obaydi, S., Hennrikus, E. F., Mohammad, N., Lehman, E. B., Thakur, A., & Al‐Shaikhly, T. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272691 · Cited by 20
COVID-19 vaccination effectiveness rates by week and sources of bias: a retrospective cohort study
Ostropolets, A., & Hripcsak, G. M. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061126 · Cited by 18
RETRACTED: Non-coding RNA in SARS-CoV-2: Progress toward therapeutic significance
Shirvani, H., Jafari, H., Moravveji, S. S., Faranghizadeh, F. A., Talebi, M., Ghanavi, J., Esfandi, F., Najafi, S., Moghadam, M. N., Farnia, P., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.09.105 · Cited by 20
RetractedLigand-based drug repurposing strategy identified SARS-CoV-2 RNA G-quadruplex binders
Moraca, F., Marzano, S., D’Amico, F., Lupia, A., Fonzo, S. D., Vertecchi, E., Salvati, E., Porzio, A. D., Catalanotti, B., Randazzo, A., et al. (2022) · Chemical Communications · doi:10.1039/d2cc03135c · Cited by 20
Wan, E. Y. F., Mok, A. H. Y., Yan, V. K. C., Chan, C. I. Y., Wang, B., Lai, F. T. T., Chui, C. S. L., Li, X., Wong, C. K. H., Lau, C. S., et al. (2022) · Journal of Travel Medicine · doi:10.1093/jtm/taac119 · Cited by 21
“Some observational evidence suggests strong and durable protection against severe disease and death from both mRNA and inactivated vaccines, with transient protection against milder symptomatic disease.(20,21) However, most existing vaccineeffectiveness estimates focused primarily on mRNA vaccine as the exposure, whil…”
BackgroundA Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds
Usdan, L. S., Patel, S., Rodriguez, H., Xu, X., Lee, D.-Y., Finn, D., Wyper, H., Lowry, F. S., Mensa, F., Lu, C., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad718 · Cited by 20
“…continued to provide broad protection against COVID-19 caused by dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants [4– 6], more antigenically distinct Omicron variants with increased immune escape potential have limited the vaccine’s effectiveness against mild…”
BackgroundPreventing a cluster from becoming a new wave in settings with zero community COVID-19 cases
Abeysuriya, R., Delport, D., Stuart, R. M., Sacks‐Davis, R., Kerr, C. C., Mistry, D., Klein, D. J., Hellard, M. E., & Scott, N. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07180-1 · Cited by 18
“Several effective vaccines were developed in late 2020 [9–12] but with limited availability and logistical challenges in global distribution [13], in the near future non-pharmaceutical interventions will continue to remain the primary mechanism for managing the pandemic in many countries.”
BackgroundMalcangi, G., Inchingolo, A. D., Inchingolo, A. M., Santacroce, L., Marinelli, G., Mancini, A., Vimercati, L., Maggiore, M. E., D’Oria, M. T., Hazballa, D., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9091964 · Cited by 31
Clemens, J. D., Aziz, A. B., Tadesse, B. T., Kang, S. S. Y., Marks, F., & Kim, J. H. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101253 · Cited by 17
Jergović, M., Uhrlaub, J. L., Watanabe, M., Bradshaw, C. M., White, L. M., LaFleur, B., Edwards, T., Sprissler, R. S., Worobey, M., Bhattacharya, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30617-9 · Cited by 21
Muhsen, K., Maimon, N., Mizrahi, A., Varticovschi, B., Bodenheimer, O., Cohen, D., & Dagan, R. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.19940 · Cited by 18
Kantauskaitė, M., Müller, L., Hillebrandt, J., Lamberti, J., Fischer, S., Kolb, T., Ivens, K., Koch, M., Andrée, M., Lübke, N., et al. (2022) · Clinical Transplantation · doi:10.1111/ctr.14790 · Cited by 18
Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination
Fryer, H. A., Hartley, G. E., Edwards, E. S. J., O’Hehir, R. E., & van Zelm, M. C. (2022) · Biochemical Society Transactions · doi:10.1042/bst20220415 · Cited by 16
Competition of SARS-CoV-2 variants on the pandemic transmission dynamics
Chen, J., Gu, C., Ruan, Z., & Tang, M. (2023) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2023.113193 · Cited by 19
“mutation, D614G, took over the world in July 2020 [2].”
BackgroundBibliometric Analysis of Global Scientific Production on COVID-19 and Vaccines
Neto, A. R. D. S., de Carvalho, A. R. B., da Silva, M. D. F., Neta, M. M. R., Sena, I. V. D. O., Almeida, R. N., Filha, F. S. S. C., Silva, L. L. L. E., da Costa, G. R., Lira, I. M. D. S., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20064796 · Cited by 20
Park, W. B., Hwang, Y. H., & Cheong, H. J. (2023) · Infection and Chemotherapy · doi:10.3947/ic.2023.0023 · Cited by 19
“https://doi.org/10.3947/ic.2023.0023 emergency department visits and hospitalizations due to COVID-19, respectively and >90% effective in reducing asymptomatic and symptomatic infections, hospitalizations, and deaths due to COVID-19 [33, 34].”
InfluentialCOVID-19 Vaccines and Myocarditis: An Overview of Current Evidence
Hromić‐Jahjefendić, A., Sezer, A., Aljabali, A. A. A., Serrano‐Aroca, Á., Tambuwala, M. M., Uversky, V. N., Redwan, E. M. M. M., Barh, D., & Lundstrom, K. H. (2023) · Biomedicines · doi:10.3390/biomedicines11051469 · Cited by 19
“However, the introduction of various COVID-19 vaccines has led to a considerable decrease in COVID-19-related morbidity and death around the world, and all licensed COVID-19 vaccines have shown advantages that outweigh the possible dangers among various age groups [15,16].”
Uddin, K. M. A., Prity, F. S., Tasnim, M., Jannat, S. N., Faruk, M. O., Islam, J., Murad, S. A., Adhikary, A., & Bairagi, A. K. (2023) · Human-Centric Intelligent Systems · doi:10.1007/s44230-023-00049-9 · Cited by 19
“Encouragingly, the hospitalization rate for individuals over 80 years experienced a staggering reduction of 80%, while those aged 50 to 70 exhibited a hospitalization rate on par with the pre-vaccination era [62].”
Examining SARS-CoV-2 Interventions in Residential Colleges Using an Empirical Network
Hambridge, H. L., Kahn, R. J., & Onnela, J.-P. “. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.10.008 · Cited by 18
Li, R., Li, Y., Zou, Z., Liu, Y., Li, X., Zhuang, G., Shen, M., & Zhang, L. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2021.801763 · Cited by 20
Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant
Yang, W., Greene, S. K., Peterson, E. R., Li, W., Mathes, R. W., Graf, L. E., Lall, R., Hughes, S., Wang, J., & Fine, A. D. (2022) · Science Advances · doi:10.1126/sciadv.abm0300 · Cited by 18
Melton, A., Doyle‐Meyers, L. A., Blair, R. V., Midkiff, C. C., Melton, H. J., Russell‐Lodrigue, K., Aye, P. P., Schiro, F. R., Fahlberg, M. D., Szeltner, D. M., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010162 · Cited by 19
Caironi, V., Pitoia, F., & Trimboli, P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.900964 · Cited by 19
Stopping the misinformation: BNT162b2 COVID-19 vaccine has no negative effect on women’s fertilityPreprint
Safrai, M., Rottenstreich, A., Herzberg, S., Imbar, T., Reubinoff, B. E., & Ben‐Meir, A. (2021) · medRxiv · doi:10.1101/2021.05.30.21258079 · Cited by 19
Reduced mortality rate after coronavac vaccine among healthcare workers
Akpolat, T., & Uzun, O. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.06.005 · Cited by 18
Wu, T., Kang, S., Peng, W., Zuo, C., Zhu, Y., Pan, L., Fu, K., You, Y., Yang, X., Luo, X., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.702066 · Cited by 21
Metadata
- Authors
- Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., Southern, J., Swerdlow, D. L., Jodar, L., Levy, Y., & Alroy-Preis, S.
- Affiliations
- Ben-Gurion University of the Negev (IL)
- Pfizer (United States) (US)
- Hebrew University of Jerusalem (IL)
- Israel Ministry of Health (IL)
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-05
- Volume
- 397
- Issue
- 10287
- Pages
- 1819-1829
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC8099315
- OpenAlex
- W3158276912
- Semantic Scholar
- 096d4aae680648191460c8297e1a9d74c3a73c03
- Cited by
- 1,564
- References
- 19
- Citations by year
- 2026: 36 · 2025: 68 · 2024: 161 · 2023: 277 · 2022: 604 · 2021: 417
- FWCI
- 115.42
- Type
- journal article
- Language
- en
- Update notices
- erratum (2021-07-17)
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Harvard University
- Weizmann Institute of Science
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 mRNA vaccine, SARS-CoV-2, COVID-19 vaccine effectiveness, real-world effectiveness, COVID-19 hospitalization, COVID-19 mortality, asymptomatic infection, symptomatic infection, vaccine uptake, B.1.1.7 variant, public health impact
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Aged, 80 and over, Female, Hospitalization, Humans, Israel, Male, Middle Aged, Population Surveillance, RNA, Messenger, Incidence, Mass Vaccination, Young Adult, Asymptomatic Infections, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
